ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca's Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma.Original Article
You may also like
Nouscom to present re‑treatment data in Lynch...
ViiV Healthcare to unveil new HIV treatment data at...
Almirall’s paediatric registration of Ebglyss for...
The Bloc appoints Jon Chapman as European Executive...
UCSD, IGI Partnership Expands CRISPR Innovation Across...
10x Clinical Expansion Advances with CLIA Lab Plans...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.